About Invokana (canagliflozin) - After first line, take a firm line
Invokana Efficacy Icon

Efficacy

Invokana has been shown to achieve consistent lowering of HbA1c across clinical trials at both 100mg and 300mg doses

  • In phase III trials, greater than 0.8% reduction in HbA1c was demonstrated with Invokana 100mg. 1–4

HbA1c change from baseline (LOCF) achieved with Invokana 100mg in phase III trials

HbA1c change from baseline (LOCF) achieved with Invokana 100mg in phase III trials - Invokana (canagliflozin) Chart

Invokana 300mg: the only SGLT2 inhibitor to demonstrate greater than 1% reductions in HbA1c at primary endpoint in four phase III clinical trials from a baseline of ≤8.1% 3-6

Invokana 300mg: the only SGLT2 inhibitor to demonstrate greater than 1% reductions in HbA1c at primary endpoint in four phase III clinical trials from a baseline of ≤8.1% - Invokana (canagliflozin) Chart

Encourage commitment with early, visible achievements

Invokana is the only SGLT2i to have demonstrated significant and sustained body weight reductions over 6.5 years (versus placebo) (p<0.001). 7

Invokana is the only SGLT2i to have demonstrated significant and sustained body weight reductions over 6.5 years (versus placebo) (p
  • Invokana 100mg and 300mg led to statistically significant reductions in body weight compared with sitagliptin (DPP4i) as an add on to metformin. 1
  • In clinical trials, Invokana 100mg and 300mg demonstrated a significant reduction in mean systolic blood pressure, –3.3mmHg and –4.6mmHg, respectively, when used as an add-on to metformin. 2
References
  1. Lavalle-González FJ et al. Diabetologia 2013;56(12):2582-92
  2. Cefalu WT et al. The Lancet 2013;382(9896):941-50
  3. Forst T et al. Diabetes Obes Metab 2014;16:467-77
  4. Wilding JPH et al. J Clin Pract 2013;67(12):1267-1282
  5. Stenlōf K et al. Diabetes Obes Metab 2013;15(4):372-82
  6. Schernthaner G et al. Diabetes Care 2013;36(9):2508-15
  7. Neal B et al. N Engl J Med 2017;377:644-57